Haemonetics (HAE)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-14
$106.20-0.10%
Close 2026-09-15 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-14
Research Workspace
Put HAE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 0% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 15%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 40% in its worst 12-month stretch.
View RiskHAE's growth depends on expanding organic revenue by 3-6% for fiscal 2027. Revenue grew 5.6% year over year, and the latest quarter beat expectations. HAE trades at 20× P/E versus a peer median of 22×, indicating modest expectations compared to our view. The next-quarter miss probability is 24%, which poses a specific risk if guidance is cut. Peer multiples imply a price roughly in line with where it trades.
Trailing returns as of 2026-09-15. HAE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 11 analysts currently covering HAE (as of Sep 2026).
Based on 5 Wall Street analysts offering 12-month price targets for HAE in the last 4 months.
Continue this research
Compare HAE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HAE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put HAE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand organic revenue by 3-6% for fiscal 2027
AI strategy win supports organic revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $106.20
The last 12 months of price, then the range of analyst 12-month targets from today’s $106.20.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand organic revenue by 3-6% for fiscal 2027
CSL Plasma deal supports revenue growth objectives.
Advances: Expand organic revenue by 3-6% for fiscal 2027
Supply agreement supports organic revenue growth objective.
Advances: Expand organic revenue by 3-6% for fiscal 2027
Raised guidance supports organic revenue growth objective.
Earnings beat supports revenue growth objective.
Advances: Expand organic revenue by 3-6% for fiscal 2027
Q2 growth supports organic revenue expansion objective.
Advances: Expand organic revenue by 3-6% for fiscal 2027
Raised guidance supports organic revenue growth objective.
Advances: Expand organic revenue by 3-6% for fiscal 2027
Forecasted revenue growth aligns with management's targets.
